Fundraise / allotmentFiled on BSE ·
Gujarat Themis Biosyn Ltd allots ₹585 crore NCDs via private placement on 16-09-2026
Guj. Themis Bio. · Pharmaceuticals & Biotechnology
What the filing says
- Issued 58,500 secured, redeemable, unlisted, rated NCDs worth ₹585 crore in two series
- Series 1: 29,500 NCDs (₹295 crore), 60 months tenure, 10% p.a. interest compounded monthly
- Series 2: 29,000 NCDs (₹290 crore), 18 months tenure, 17.75% p.a. interest compounded monthly
Original filing
Announcement under Regulation 30 (LODR)-Allotment
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue: Rank 1Margin: Rank 1
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Guj. Themis Bio.
- Acquisition / mergerGujarat Themis Biosyn Ltd. completes acquisition of MicroBiopharm Japan Co., Ltd.
- Fundraise / allotmentGujarat Themis Biosyn approves issuance of Non-Convertible Debentures up to ₹585 Cr
- Fundraise / allotmentGujarat Themis Biosyn Ltd announces Board meeting on September 10, 2026
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentInox GreenInox Green Energy Services Ltd allotted 1.81 crore equity shares via QIP in Sept 2026
- Fundraise / allotmentInox GreenInox Green Energy Services completes Qualified Institutions Placement on Sept 29, 2026
- Fundraise / allotmentBharat Parenterals LtdBharat Parenterals Limited approves preferential allotment of 9.13 lakh equity shares
- Fundraise / allotmentAurum Proptech LtdAurum PropTech allots 1.98 crore equity shares to REA India on preferential basis
- Fundraise / allotmentAurum Proptech LtdAurum PropTech Limited allots 1.98 crore shares to REA India on preferential basis
- Fundraise / allotmentRepco Home FinRepco Home Finance approved raising ₹1500 Cr NCDs and ₹1000 Cr Commercial Paper
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.